Revolution Medicines Inc (RVMD) Stock Price, Quote & News

Company Profile

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6801

Website: www.revmed.com

Address:

700 Saginaw Drive, Redwood City, United States

JuggernautRaider Aug. 8 at 6:50 AM

$TNXP we shall see! I have been busy $ALT $RVMD $BMY all strong toon

1 · Reply

Mattyk7 Aug. 8 at 12:14 AM

$RVMD $VSTM Verastem is at such a discount 600M vs Revolution at 40+B over bought with studies on par with Verastem. I’m selling all RVMD and adding to VSTM position. No brainer. Squeeze incoming

2 · Reply

JFais Aug. 7 at 8:47 PM

$VSTM (NP) +14% on Q2 update October KRAS data (likely ESMO) will be "meaningful" and include 20 patients each for pancreatic, lung and CRC with early look at durability. The bar they've set is 30% ORR with 6 month DoR ( $REPL's RP1 just approved with 24% ORR in melanoma) Believe the big differentiator vs pan-RAS ( $RVMD et al) will be tolerability (should allow them to hit the target harder and get a deeper response, hopefully better durability) They are already starting to see that in the data (sounds bullish) Believe they are seeing more consistent responses, deeper responses, and eventually more prolonged responses due to very tolerable doses. No rash and mucositis. Are seeing diarrhea, nausea and vomiting as main AEs. Drug irritates the stomach and causes some GI distress, but that does not go up with dose

0 · Reply

WAJeff Aug. 7 at 8:11 PM

$RVMD $205.90 ath

0 · Reply

EmSol Aug. 7 at 7:42 PM

$RVMD another ATH on Friday with great and strong way to break $200 cheers

0 · Reply

EmSol Aug. 7 at 7:37 PM

$RVMD que le rêve continue:) see you at $250

0 · Reply

FlowAnomaly Aug. 7 at 5:46 PM

$RVMD interesting call coming in

0 · Reply

SellasgpsCurativeBAT11 Aug. 7 at 4:22 PM

$SLS Correct! Plus these numbers don’t include July/August 2026 buys. I have been saying for months now. We will see Tutes at over 80% after BO. Same exact pattern at $CDTX $RVMD $ABVX Before they hit triple digits. CURATIVE GPS Data+ Smart money buying hand over fist right before BO. ✌️🙏❤️‍🩹

0 · Reply

AlphaResearchHQ Aug. 7 at 4:05 PM

JUST UPDATED ITS STOCK PORTFOLIO 📊 (Part 2) Google’s Q2 portfolio update continues with more positions revealed: 🤖 $RVMD — 2,946,619 shares ☁️ $FRSH — 16,206,643 shares 🧬 $PRBX — 4,919,498 shares 🚀 $TEM — 1,551,102 shares 💻 $GTLB — 2,724,712 shares What stands out here is the focus on innovative technology, cloud software, and next-generation growth companies. Big institutional portfolios can offer valuable insight into where long-term capital is looking. These positions don’t guarantee future performance, but they are worth keeping on the radar as these themes continue developing. I’ll be watching how these names perform and whether investor interest starts rotating back into these growth areas. The next move usually starts before everyone notices. Stay prepared, not reactive.

0 · Reply

SellasgpsCurativeBAT11 Aug. 7 at 3:52 PM

$SLS $CDTX $RVMD $ABVX I saw the same filings at $CDTX $RVMD $ABVX before their massive jump to triple digits. Smart money is accumulating at an incredible pace. ✌️🙏❤️‍🩹

0 · Reply

Revolution Medicines price target raised to $227 from $205 at JPMorgan

2026-08-06T12:56:21.000Z - 1 day ago

Revolution Medicines price target raised to $230 from $220 at Evercore ISI

2026-08-06T12:48:10.000Z - 1 day ago

Revolution Medicines price target raised to $201 from $192.10 at Wedbush

2026-08-06T12:25:42.000Z - 1 day ago

Revolution Medicines price target raised to $230 from $195 at Oppenheimer

2026-08-06T11:11:49.000Z - 2 days ago

Revolution Medicines price target raised to $203 from $182 at RBC Capital

2026-08-06T10:42:28.000Z - 2 days ago

Revolution Medicines price target raised to $240 from $235 at Guggenheim

2026-08-05T20:41:32.000Z - 2 days ago

Revolution Medicines reports Q2 EPS ($3.06), consensus ($2.06)

Aug 5, 2026, 4:30 PM EDT - 2 days ago

Revolution Medicines Earnings Call Transcript: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 2 days ago

Revolution Medicines Earnings release: Q2 2026

Aug 5, 2026, 4:30 PM EDT - 2 days ago

Revolution Medicines Quarterly report: Q2 2026

Aug 5, 2026, 4:02 PM EDT - 2 days ago

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Aug 1, 2026, 8:00 AM EDT - 6 days ago

Revolution Medicines Slides: Corporate presentation

Jul 29, 2026, 4:05 PM EDT - 9 days ago

Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026

2026-07-23T12:45:38.000Z - 15 days ago

Revolution Medicines price target raised to $192.10 from $181 at Wedbush

2026-07-22T21:05:34.000Z - 16 days ago

Revolution Medicines receives FDA review acceptance for daraxonrasib

Jul 22, 2026, 4:05 PM EDT - 16 days ago

Revolution Medicines' New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer

2026-07-17T11:26:06.000Z - 21 days ago

Tango Therapeutics price target raised to $40 from $36 at Mizuho

TNGX

2026-07-09T11:30:47.000Z - 4 weeks ago

Revolution Medicines price target raised to $235 from $205 at Guggenheim

2026-07-07T13:30:28.000Z - 4 weeks ago

EMA accelerates assessment of Revolution Medicines daraxonrasib

Jul 7, 2026, 9:23 AM EDT - 4 weeks ago

European Medicines Agency Expedites Assessment of Revolution Medicines' Daraxonrasib Under Phased Review Process

Jul 7, 2026, 9:09 AM EDT - 4 weeks ago

EMA fast-tracks review of Revolutions' experimental pancreatic cancer pill

2026-07-06T12:20:50.000Z - 4 weeks ago

Revolution Medicines price target raised to $215 from $185 at Mizuho

Jul 2, 2026, 8:00 AM EDT - 5 weeks ago

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

2026-06-30T11:21:12.000Z - 5 weeks ago

Revolution Medicines price target raised to $210 from $179 at Truist

2026-06-29T12:10:28.000Z - 5 weeks ago

Revolution Medicines price target raised to $235 from $183 at Needham

Jun 24, 2026, 7:31 PM EDT - 6 weeks ago

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

2026-06-23T16:46:48.000Z - 6 weeks ago

Revolution Medicines begins treating patients in RASolute 305 trial

Jun 22, 2026, 8:00 AM EDT - 6 weeks ago

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

2026-06-08T13:50:25.000Z - 2 months ago

RBC Capital says Tango-Revolution data strengthens daraxonrasib’s PDAC position

TNGX

2026-06-08T11:14:10.000Z - 2 months ago

Tango Therapeutics announces data from study of vopimetostat, daraxonrasib

TNGX

2026-06-02T12:39:39.000Z - 2 months ago

Revolution Medicines price target raised to $182 from $165 at RBC Capital

Jun 1, 2026, 6:34 AM EDT - 2 months ago

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

ONC SMMT

May 31, 2026, 7:00 PM EDT - 2 months ago

Revolution Medicines Transcript: Study result

May 31, 2026, 7:00 PM EDT - 2 months ago

Revolution Medicines Slides: Study result

May 31, 2026, 7:00 PM EDT - 2 months ago

Revolution Medicines Press release: Study result

May 31, 2026, 8:06 AM EDT - 2 months ago

Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

May 31, 2026, 8:02 AM EDT - 2 months ago

Revolution's pancreatic cancer drug doubles survival, boosts quality of life

RVMDW

May 21, 2026, 4:05 PM EDT - 2 months ago

Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

May 14, 2026, 6:04 AM EDT - 3 months ago

US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug

May 6, 2026, 6:00 PM EDT - 3 months ago

Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

May 6, 2026, 5:01 PM EDT - 3 months ago

Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects

May 6, 2026, 4:30 PM EDT - 3 months ago

Revolution Medicines Earnings Call Transcript: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Revolution Medicines Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 3 months ago

Revolution Medicines Quarterly report: Q1 2026

May 6, 2026, 4:02 PM EDT - 3 months ago

Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

May 6, 2026, 4:00 PM EDT - 3 months ago

Revolution Medicines Slides: Corporate presentation

May 1, 2026, 12:54 PM EDT - 3 months ago

US FDA authorizes early access to Revolution's pancreatic cancer pill

Apr 29, 2026, 4:05 PM EDT - 3 months ago

Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Revolution Medicines Proxy statement: Proxy filing

Apr 28, 2026, 5:30 AM EDT - 3 months ago

There's a Revolution in Cancer. But Can Big Pharma Afford It?

Apr 27, 2026, 8:00 AM EDT - 3 months ago

Revolution Medicines Proxy statement: Proxy filing

Apr 21, 2026, 5:35 PM EDT - 3 months ago

Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

Apr 21, 2026, 5:35 PM EDT - 3 months ago

Two experimental drugs showed striking early results against pancreatic cancer

BNTX

Apr 21, 2026, 5:30 PM EDT - 3 months ago

Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting

Apr 21, 2026, 11:23 AM EDT - 3 months ago

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

Apr 19, 2026, 2:00 PM EDT - 3 months ago

Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting

Apr 17, 2026, 4:02 PM EDT - 4 months ago

Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 15, 2026, 12:10 PM EDT - 4 months ago

This Pill May Help Pancreatic Cancer Patients Live Longer

Apr 15, 2026, 12:41 AM EDT - 4 months ago

Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes

Apr 13, 2026, 4:01 PM EDT - 4 months ago

Revolution Medicines, Inc. Announces Proposed Offerings of Common Stock and Convertible Senior Notes

Apr 13, 2026, 10:13 AM EDT - 4 months ago

Revolution Medicines surges 38% as pancreatic cancer drug shows breakthrough

Apr 13, 2026, 9:45 AM EDT - 4 months ago

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial.

Apr 13, 2026, 9:11 AM EDT - 4 months ago

This Biotech Stock Soars 38%. Pancreatic Cancer Trial Was a Success.

Apr 13, 2026, 8:06 AM EDT - 4 months ago

Revolution Medicines' experimental cancer pill helps improve survival in late-stage study

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Revolution Medicines' potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Apr 10, 2026, 1:49 PM EDT - 4 months ago

Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer

Mar 17, 2026, 6:37 PM EDT - 5 months ago

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting

Mar 3, 2026, 9:50 AM EST - 5 months ago

Revolution Medicines Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 4:30 PM EST - 5 months ago

Revolution Medicines Earnings Call Transcript: Q4 2025

Feb 25, 2026, 4:30 PM EST - 5 months ago

Revolution Medicines Annual report: Q4 2025

Feb 25, 2026, 4:30 PM EST - 5 months ago

Revolution Medicines Earnings release: Q4 2025

Feb 25, 2026, 4:02 PM EST - 5 months ago

Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

Feb 25, 2026, 7:00 AM EST - 5 months ago

Revolution Medicines Slides: Corporate presentation

Feb 24, 2026, 4:05 PM EST - 5 months ago

Revolution Medicines to Participate in TD Cowen 46th Annual Health Care Conference

Feb 18, 2026, 4:05 PM EST - 6 months ago

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2025 After Market Close on February 25, 2026

Feb 11, 2026, 9:30 AM EST - 6 months ago

Revolution Medicines Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 4:05 PM EST - 6 months ago

Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 26, 2026, 4:30 PM EST - 6 months ago

Overlooked Stock: RVMD Sells After MRK Turns Away

MRK

Jan 25, 2026, 3:27 PM EST - 6 months ago

Merck no longer in talks to buy Revolution Medicines, WSJ reports

MRK

Jan 25, 2026, 2:30 PM EST - 6 months ago

Merck No Longer in Talks to Buy Revolution Medicines

MRK

Jan 12, 2026, 1:30 PM EST - 7 months ago

Revolution Medicines Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 1:30 PM EST - 7 months ago

Revolution Medicines Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 9, 2026, 2:58 PM EST - 7 months ago

Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion

MRK

Jan 9, 2026, 5:54 AM EST - 7 months ago

Revolution Medicines Stock Soars. Takeover Buzz Grows, Another Suitor Emerges.

Jan 8, 2026, 3:56 PM EST - 7 months ago

Merck in talks to buy biotech Revolution Medicines, FT reports

MRK

Jan 8, 2026, 8:00 AM EST - 7 months ago

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib

Jan 8, 2026, 7:38 AM EST - 7 months ago

AbbVie Denies It's in Talks to Buy Revolution Medicines. Both Stocks Are Falling.

ABBV

Jan 7, 2026, 2:58 PM EST - 7 months ago

AbbVie in talks to buy biotech Revolution Medicines, WSJ reports

ABBV

Jan 7, 2026, 2:48 PM EST - 7 months ago

AbbVie Near Deal for Revolution Medicines

ABBV

Jan 5, 2026, 4:05 PM EST - 7 months ago

Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference

JuggernautRaider Aug. 8 at 6:50 AM

$TNXP we shall see! I have been busy $ALT $RVMD $BMY all strong toon

1 · Reply

Mattyk7 Aug. 8 at 12:14 AM

$RVMD $VSTM Verastem is at such a discount 600M vs Revolution at 40+B over bought with studies on par with Verastem. I’m selling all RVMD and adding to VSTM position. No brainer. Squeeze incoming

2 · Reply

JFais Aug. 7 at 8:47 PM

0 · Reply

WAJeff Aug. 7 at 8:11 PM

$RVMD $205.90 ath

0 · Reply

EmSol Aug. 7 at 7:42 PM

$RVMD another ATH on Friday with great and strong way to break $200 cheers

0 · Reply

EmSol Aug. 7 at 7:37 PM

$RVMD que le rêve continue:) see you at $250

0 · Reply

FlowAnomaly Aug. 7 at 5:46 PM

$RVMD interesting call coming in

0 · Reply

SellasgpsCurativeBAT11 Aug. 7 at 4:22 PM

0 · Reply

AlphaResearchHQ Aug. 7 at 4:05 PM

0 · Reply

SellasgpsCurativeBAT11 Aug. 7 at 3:52 PM

$SLS $CDTX $RVMD $ABVX I saw the same filings at $CDTX $RVMD $ABVX before their massive jump to triple digits. Smart money is accumulating at an incredible pace. ✌️🙏❤️‍🩹

0 · Reply

EquityResearch6 Aug. 7 at 2:38 PM

GOOGLE $GOOGL JUST UPDATED ITS STOCK PORTFOLIO. Here are the major holdings as of the end of Q2: $ARM — Arm Holdings 1,960,784 shares $RVMD — Revolution Medicines 2,946,619 shares $FRSH — Freshworks 16,206,643 shares $TEM — Tempus AI 1,551,102 shares Google’s portfolio shows exposure across several long-term innovation themes. Big technology companies often invest years ahead of mainstream adoption. Watching where companies like Google deploy capital can provide insight into the future technology landscape. Follow my profile for more AI, space, and next-generation technology trends. NFA. DYOR.

1 · Reply

atreus57 Aug. 7 at 1:27 PM

$RNXT starting to look like a real commercial-regime change, not just a microcap biotech trade. Closed $1.15 +8.5% yesterday on ~694K vol (~2.5x avg) after the FIRST commercial RenovoCath use in sarcoma at existing customer CARTI — real-world expansion beyond pancreatic cancer. Q1: $563K sales (+136% QoQ), ~85% gross margin, 16 active centers + 32 in pipeline. Company says Aug 12 Q2 call will discuss GROWING revenue, increased adoption + broader repeat orders. Aug 13 JonesTrading KOL: Moffitt + AdventHealth. Bull triggers: Q2 >Q1 sales, more active centers/repeat use + TIGeR-PaC enrollment completion. Chart: $1.18-1.20 breakout → $1.45 52wk high → $1.75 warrant zone. For $TMDX $IOVA $RVMD $IMRX watchers: $RNXT sits at an unusual intersection of commercial medtech + solid-tumor oncology + Phase III optionality. Bullish. Watching execution, not hype.

1 · Reply

StockConsultant Aug. 7 at 1:26 PM

$RVMD Revolution Medicines stock, with a top of range breakout at https://www.stockconsultant.com/?RVMD

0 · Reply

EmSol Aug. 7 at 11:57 AM

$RVMD are we at $250 yet! 40 B MC no drug yet, work for me.. :)

0 · Reply

shopno Aug. 7 at 5:17 AM

$SLS exactly. MRK offered $28-32 Billions to acquire RVMD, which the latter declined. The top mark was $4B higher than the bottom mark ($28B). That $4B negotiation threshold itself is ~170% of today's SLS market cap. BTW, $RVMD reached ~30% higher peak valuation than the higher mark. No biotech probably ever enjoyed a $40B+ market cap with $0 revenue. If RVMD gets acquired before full scale launch, I guess BO can go as high as$50B. Or they remain independent. Either is fine as an investor.

1 · Reply

Jackie_O_II Aug. 7 at 3:37 AM

$RVMD 🤗

0 · Reply

JFDI Aug. 6 at 10:25 PM

$RVMD out of 6wt.

0 · Reply

combat_cannabis Aug. 6 at 9:16 PM

$IMRX yup yup. Looking good here. Keep floating up.. bio techs are strong. $RVMD killing it. This is something people are looking at. Ai should advance this field

0 · Reply

Alt_Fuel Aug. 6 at 9:06 PM

$VSTM Only the beginning ... still a Huge Amount of Progress needed when compared to $RVMD ...

0 · Reply

cfromhertz Aug. 6 at 2:15 PM

$RVMD breaking out

0 · Reply

Irish_lass Aug. 6 at 2:05 PM

$RVMD Priceless!!

0 · Reply

ajkoles Aug. 6 at 1:57 PM

$SLS let’s catch up to $RVMD!

0 · Reply

Market Cap	42.05B
Revenue (ttm)	0.00
Net Income (ttm)	-1.13B
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.19

Volume	1,665,200
Avg Vol	2,738,348
Day's Range	N/A - N/A
Shares Out	212.60M
Stochastic %K	97%
Beta	1.39
Analysts	Strong Sell
Price Target	$208.91